A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Inclusion Criteria:

• Male and female adolescents 12 to less than 18 years of age

• Recipients of a renal allograft from a living or deceased donor transplanted atleast 6 calendar months prior to enrollment

• Receiving a stable regimen of a calcineurin inhibitor (CNI), with mycophenolatemofetil (MMF) or enteric-coated mycophenolate sodium/mycophenolate mofetil (EC-MPS/MPA), with or without daily corticosteroids for ≥ 30 days prior torandomization

• Clinically stable renal function during the 12-week period prior to screening, inthe opinion of the investigator and based on protocol-defined criteria forproteinuria and estimated glomerular filtration rate (eGFR)

• Serologic evidence of past exposure to Epstein-Barr virus (EBV) and current absenceof EBV DNA replication at or prior to renal transplantation and during the Screeningperiod

• Completion of an initial course of SARS-CoV-2 vaccination per local standard ofcare, a minimum of 6 weeks prior to enrollment

Exclusion Criteria:

• Recipients with EBV serostatus negative or unknown at screening or at transplant

• Treatment for biopsy-proven acute rejection (BPAR) of any degree of severity within 6 calendar months prior to enrollment

• Biopsy-confirmed antibody-mediated acute rejection at any time with the currentallograft

• Banff 97 grade IIA or higher acute cellular rejection (or equivalent), or treatmentwith plasmapheresis or rituximab for any acute rejection at any time with thecurrent allograft

• Current evidence or past history of active or inadequately treated latenttuberculosis (TB) infection

• Previously treated with belatacept or previously enrolled in a belatacept trial withtheir present allograft

Other inclusion/exclusion criteria apply